[Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension]. / Efecto de Combigan(®) versus placebo en el flujo sanguíneo ocular en pacientes hipertensos oculares.

PURPOSE: This study was undertaken to compare the ocular haemodynamic effects of Combigan(®) versus placebo in patients with ocular hypertension (OHT). METHODS: Thirty patients with OHT were included in a controlled, randomised, double blind study in two parallel groups; 15 were randomised to receive Combigan(®) and 15 to receive placebo for a period of 3 months. At baseline and at 3 months retrobulbar blood flowmeasurements of the ophthalmic artery (OA) and central retinal artery (CRA) were taken using colour Doppler imaging(CDI) ultrasound, concurrently with intraocular pressure (IOP). RESULTS: Combigan(®) significantly reduced IOP after 3 months of treatment (P = 0.001), whereas placebo showed no significant change in IOP. The baseline haemodynamic parameters were similar between treatment and placebo groups. Patients treated with Combigan® showed a statistically significant decrease in CRA resistive index (P = 0.007). CONCLUSIONS: Patients treated for 3 months with Combigan(®) showed a significant decrease of CRA resistive index that could be explained by the decrease in IOP.

Efecto de Combigan® versus placebo en el flujo sanguíneo ocular en pacientes hipertensos oculares / Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension

Propósito: Estudiar los cambios hemodinámicos retrobulbares mediante ecografía dopplercolor, en pacientes hipertensos oculares (HTO) en tratamiento con Combigan® versus placebo.Método: Treinta pacientes randomizados en 2 grupos paralelos fueron incluidos en un estudioprospectivo y a doble ciego; quince de ellos en tratamiento con Combigan® y quince entratamiento con placebo, durante un periodo de 3 meses. Se obtuvieron medidas de la presiónintraocular (PIO) y del flujo sanguíneo a nivel de la arteria central de la retina (ACR) y la arteriaoftámica en el momento basal y a los 3 meses.Resultados: Combigan® redujo significativamente la PIO tras tres meses de tratamiento(p = 0,001). Los parámetros hemodinámicos basales fueron similares entre los grupos placeboy tratamiento. Los pacientes tratados con Combigan® mostraron un descenso estadísticamentesignificativo del índice de resistencia de la ACR (p = 0,007).Conclusiones: Los pacientes tratados durante 3. meses con Combigan® mostraron un descensoestadísticamente significativo del índice de resistenciade la ACR que podría explicarsepor el descenso de PIO(AU)

Purpose: This study was undertaken to compare the ocular haemodynamic effects ofCombigan® versus placebo in patients with ocular hypertension (OHT).Methods: Thirty patients with OHT were included in a controlled, randomised, double blindstudy in two parallel groups; 15 were randomised to receive Combigan® and 15 to receiveplacebo for a period of 3 months. At baseline and at 3 months retrobulbar blood flowmeasurementsof the ophthalmic artery (OA) and central retinal artery (CRA) were taken usingcolour Doppler imaging(CDI) ultrasound, concurrently with intraocular pressure (IOP). Results: Combigan® significantly reduced IOP after 3 months of treatment (P = 0.001), whereasplacebo showed no significant change in IOP. The baseline haemodynamic parameters weresimilar between treatment and placebo groups. Patients treated with Combigan® showed astatistically significant decrease in CRA resistive index (P = 0.007).Conclusions: Patients treated for 3 months with Combigan® showed a significant decrease ofCRA resistive index that could be explained by the decrease in IOP(AU)

[Evaluation of the effect of bimatoprost/timolol fixed combination on ocular blood flow in patients with ocular hypertension using colour Doppler imaging. Preliminary study]. / Evaluación mediante ecografía doppler color del efecto de la combinación fija bimatoprost/timolol sobre el flujo sanguíneo ocular en pacientes con hipertensión ocular. Estudio preliminar.

PURPOSE: To investigate the effects of topical bimatoprost (0.3 mg/ml)/timolol maleate (5 mg/ ml) fixed combination on retrobulbar blood flow in patients with ocular hypertension (OHT). PATIENTS AND METHODS: Twenty consecutive patients with OHT were prospectively randomised to either bimatoprost/timolol or placebo during a 12 weeks double masked treatment trial. Examinations were performed at baseline and after 12 weeks of treatment. Visual acuity, intraocular pressure (IOP), slit-lamp examination, automated static perimetry, systemic blood pressure and heart rate were all recorded. Retrobulbar blood flow measurements of the ophthalmic artery (AO) and central retinal artery (CRA) were measured by colour Doppler imaging. RESULTS: IOP was significantly decreased by bimatoprost/timolol fixed combination (p < 0.0001). Bimatoprost/timolol fixed combination therapy resulted in a significant increase in end diastolic velocity (EDV) of the CRA (p = 0.03). In patients treated with bimatoprost/timolol a statistically significant correlation between IOP and EDV was observed after 12 weeks of treatment (r = -0.511, p = 0.045). The systolic (p = 0.54) and diastolic (p = 0.67) blood pressures and heart rate (p = 0.10) did not show statistically significant differences during the study period. CONCLUSIONS: Topical bimatoprost/timolol fixed combination significantly reduced IOP in patients with OHT. However, the only significant change observed in retrobulbar haemodynamics was an increase in EDV of the CRA, probably associated with a reduction in IOP.

Evaluación mediante ecografía doppler color del efecto de la combinación fija bimatoprost/timolol sobre el flujo sanguíneo ocular en pacientes con hipertensión ocular. Estudio preliminar / Evaluation of the effect of bimatoprost/timolol fixed combination on ocular blood flow in patients with ocular hypertension using colour Doppler imaging. Preliminary study

Objetivo: Evaluar el efecto de la administración tópica de la combinación fija bimatoprost(0,3 mg/ml)/maleato de timolol (5 mg/ml) sobre el flujo sanguíneo retrobulbar en pacientescon hipertensión ocular (HTO).Pacientes y métodos: Veinte pacientes con HTO fueron incluidos en este estudio prospectivo,doble ciego y aleatorizados a recibir tratamiento con bimatoprost/timolol o placebo durante12 semanas. Las pruebas se llevaron a cabo en la primera visita y a las 12 semanas. Seregistraron la agudeza visual, presión intraocular (PIO), examen en lámpara de hendidura,perimetría estática automática, presión arterial sistémica y frecuencia cardíaca. Medianteecografía doppler color (EDC) se midieron los parámetros del flujo sanguíneo retrobulbarde la arteria oftálmica (AO) y arteria central de la retina (ACR).Resultados: La combinación fija bimatoprost/timolol redujo significativamente la PIO(p < 0,0001), además de conseguir un incremento significativo de la velocidad diastólicafinal (VDF) en la ACR (p = 0,03). En el grupo de pacientes tratados con bimatoprost/timololse observó una correlación estadísticamente significativa entre la PIO y la VDF a las 12semanas de tratamiento (r = –0,511, p = 0,045). No hubo cambios significativos en las presionesarteriales sistólica (p = 0,54) y diastólica (p = 0,67) ni en la frecuencia cardíaca(p = 0,10) durante el período de tratamiento.Conclusiones: La combinación fija bimatoprost/timolol redujo significativamente la PIO enpacientes con HTO. El único cambio observado en la hemodinámica retrobulbar fue unincremento de la VDF en la ACR, probablemente relacionado con la reducción de la PIO(AU)

Purpose: To investigate the effects of topical bimatoprost (0.3 mg/ml)/timolol maleate (5 mg/ml) fixed combination on retrobulbar blood flow in patients with ocular hypertension(OHT).Patients and methods: Twenty consecutive patients with OHT were prospectively randomisedto either bimatoprost/timolol or placebo during a 12 weeks double masked treatment trial.Examinations were performed at baseline and after 12 weeks of treatment. Visual acuity,intraocular pressure (IOP), slit-lamp examination, automated static perimetry, systemicblood pressure and heart rate were all recorded. Retrobulbar blood flow measurements ofthe ophthalmic artery (AO) and central retinal artery (CRA) were measured by colourDoppler imaging.Results: IOP was significantly decreased by bimatoprost/timolol fixed combination(p < 0.0001). Bimatoprost/timolol fixed combination therapy resulted in a significantincrease in end diastolic velocity (EDV) of the CRA (p = 0.03). In patients treated withbimatoprost/timolol a statistically significant correlation between IOP and EDV wasobserved after 12 weeks of treatment (r = –0.511, p = 0.045). The systolic (p = 0.54) anddiastolic (p = 0.67) blood pressures and heart rate (p = 0.10) did not show statisticallysignificant differences during the study period.Conclusions: Topical bimatoprost/timolol fixed combination significantly reduced IOP inpatients with OHT. However, the only significant change observed in retrobulbarhaemodynamics was an increase in EDV of the CRA, probably associated with a reductionin IOP(AU)

[Surgical treatment of Duane's syndrome type I by recession of the medial rectus of the affected eye and faden operation of the contralateral medial rectus]. / Tratamiento quirúrgico del síndrome de Duane, tipo I mediante retroinserción del recto medial del lado afecto y faden del recto medial contralateral.

PURPOSE: Different surgical approaches have been described for the treatment of Duane's syndrome. The purpose of our study is to report the results of patients undergoing recession of the medial rectus (MR) muscle of the affected eye and placement of contralateral MR faden posterior fixation sutures. METHODS: Retrospective study of 11 patients treated by a 4-7 mm recession of the MR of the affected eye and 13 mm faden posterior fixation suture of the contralateral MR in order to correct abnormal head position and esotropia in primary position. RESULTS: After surgery, there was no torticolis in 81.8% of patients, with less than 10 degrees of torticolis in the remainder. In all patients, postoperative esotropia was less than 5 prismatic dioptres. CONCLUSION: This is a safe and effective procedure in Duane's syndrome type I to treat moderate esotropia and torticolis.

Tratamiento quirúrgico del síndrome de Duane, tipo I mediante retroinserción del recto medial del lado afecto y faden del recto medial contralateral / Surgical treatment of Duane´s syndrome type I by recession of the medial rectus of the afected eye and faden operation of the contralateral medial rectus

Objetivo: Se han descrito numerosos tratamientos quirúrgicos para el síndrome de Duane (SD) tipo I. El objetivo de este trabajo es comunicar los resultados obtenidos en pacientes diagnosticados de SD tipo I sometidos a retroinserción del recto medial (RM) del lado afecto y operación de faden del RM contralateral. Métodos: Estudio retrospectivo sobre once pacientes con SD tipo I a los que se les realiza una retroinserción del RM del lado afecto de entre 4 y 7 mm y faden a 13 mm del RM contralateral para resolver el tortícolis y la endotropía presentes en posición primaria. Resultados: Tras la cirugía, el tortícolis desapareció en el 81,8% de los pacientes, siendo menor de 10º en el resto. En todos los pacientes la endotropía postquirúrgica fue menor de 5 dioptrías prismáticas. Conclusión: Esta técnica es un procedimiento seguro y efectivo para el tratamiento de endotropías y tortícolis moderados en el SD tipo I

Purpose: Different surgical approaches have been described for the treatment of Duane’s syndrome. The purpose of our study is to report the results of patients undergoing recession of the medial rectus (MR) muscle of the affected eye and placement of contralateral MR faden posterior fixation sutures. Methods: Retrospective study of 11 patients treated by a 4-7 mm recession of the MR of the affected eye and 13 mm faden posterior fixation suture of the contralateral MR in order to correct abnormal head position and esotropia in primary position. Results: After surgery, there was no torticolis in 81.8% of patients, with less than 10º of torticolis in the remainder. In all patients, postoperative esotropia was less than 5 prismatic dioptres. Conclusion: This is a safe and effective procedure in Duane’s syndrome type I to treat moderate esotropia and torticolis